More about Granules India Limited
Fundamentals for Granules India Limited
Regulatory Filings for Granules India Limited
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
Fundamentals for Granules India Limited
|fundrankingplaceholder|
|techrankingplaceholder|
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
Revenue projections:
GRANULES is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.
Financial Ratios:
| currentRatio | 1.801000 |
|---|---|
| forwardPE | 19.422337 |
| debtToEquity | 29.735000 |
| earningsGrowth | 0.313000 |
| revenueGrowth | 0.228000 |
| grossMargins | 0.650420 |
| operatingMargins | 0.183840 |
| trailingEps | 24.500000 |
| forwardEps | 38.950000 |
With a current ratio 1.801, GRANULES demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
GRANULES's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
Granules India Limited's low Debt-to-Equity ratio indicates that the company isn't heavily dependent on debt financing. This lower leverage reduces financial risk and enhances stability, showing that Granules India Limited is well-positioned to manage its obligations without the burden of excessive debt.
With earnings and revenue growth in positive territory, GRANULES is projected to expand its business. This strong financial performance suggests the company will continue to grow, as increased profitability and sales drive future success.
Granules India Limited's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that Granules India Limited is likely to outperform its previous year's financial performance.
Price projections:
The price of GRANULES has repeatedly been close to the lower limit of price projections. This trend suggests that the stock may be underperforming, raising concerns among investors about future performance.
Recommendation changes over time:
GRANULES has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view GRANULES as a reliable choice for their money, offering a promising avenue for future growth and financial gains.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
How Independent Directors Failed Rs 2,500 Crore in Value
India’s Stock Market May Be Sitting on a Trap